Kent Davis, MD
Family Medicine · Paris, KYNPI 1225177710
Payments from drug & device makers
Across 63 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$232
- Novo Nordisk$110
- Upsher-smith Laboratories LLC$100
- Orexo US, Inc.$78
- Novartis$72
- Exact Sciences$70
- plus $414 from 17 others
What the payments were for
- Food & beverage$1,076100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 15 | $232 |
| Novo Nordisk | 7 | $110 |
| Upsher-smith Laboratories LLC | 4 | $100 |
| Orexo US, Inc. | 4 | $78 |
| Novartis | 4 | $72 |
| Exact Sciences | 4 | $70 |
| Pfizer | 4 | $70 |
| Lilly USA, LLC | 3 | $52 |
| Almatica Pharma LLC | 3 | $48 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| GSK | 1 | $25 |
| Seqirus USA Inc | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Braeburn Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Gilead | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Medline Industries LP | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Lucid Diagnostics Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| Electromed, Inc. | 1 | $12 |
How this compares
$1,076 in reported general payments places this provider in the 55th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $64,962 |
| TrulicityDulaglutide | 37 | $35,725 |
| XareltoRivaroxaban | 36 | $30,980 |
| Nurtec OdtRimegepant Sulfate | 15 | $29,487 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $28,942 |
| EliquisApixaban | 26 | $27,419 |
| MounjaroTirzepatide | 28 | $26,165 |
| JardianceEmpagliflozin | 24 | $21,281 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,487 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $8,882 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,732 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $6,762 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 70 | $6,654 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $6,493 |
| JanuviaSitagliptin Phosphate | 11 | $6,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $110 | $64,96260 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $52 | $61,89165 claims |
| PfizerNurtec Odt, Eliquis | $70 | $56,90641 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat | $12 | $35,93355 claims |
| Johnson & JohnsonXarelto | $17 | $30,98036 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $25 | $17,09431 claims |
| AstraZenecaBreztri Aerosphere | $14 | $7,73212 claims |
| Indivior Inc.Suboxone | $232 | $1,06613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Paris
- Jeffrey GreenParis$103K
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.